IMMvention is developing therapies that inhibit multiple inflammasome pathways that result in increased cytokine production that is at the root cause of some of the following diseases.

Biotechnology

IMMvention Therapeutix

IMMvention Therapeutix's headquarters in Durham, NC, United States

Anil Goyal

Jessica Sorrentino

Marilyn Thompson

J. David Becherer

Tom Barta

Joseph Vacca

Jenny Ting

Niti Goel

The Research and Development Team at IMMvention Therapeutix is dedicated to innovating and advancing therapies that target multiple inflammasome pathways to reduce cytokine production. Comprising roles from Senior Scientist to Head of Chemistry, the team collaborates to research, design, and develop new therapeutic agents aimed at treating diseases driven by excessive cytokine activity.

Research and Development Team

The Leadership Team at IMMvention Therapeutix is responsible for guiding the company's strategic direction, overseeing research and development initiatives, and ensuring financial sustainability. Composed of the CEO, VPs of R&D and Finance, and Scientific Founders, this team collaborates to drive innovative therapy development aimed at addressing diseases linked to excessive cytokine production through inflammasome inhibition. Their collective expertise fuels the company's mission to translate scientific breakthroughs into effective therapeutic solutions.

IMMvention Therapeutix

Org chart

Board & advisors

Teams

Research and Development Team

Leadership Team

Offices

IMMvention Therapeutix

Org chart

Board & advisors

Teams

Research and Development Team

Leadership Team

Offices

Related companies